Jazz Pharmaceuticals Plc (JAZZ) Stock Price & Analysis
Jazz Pharmaceuticals Plc (JAZZ) fell 0.39% to USD 253.87 as of July 25, 2026 at 04:20 UTC, according to Nexqual real-time market data.
JAZZ last closed at USD 254.87; the session ranged USD 250.3–256.75 on volume of 538,229 shares. Market capitalization is $15.95B, with a 52-week range of USD 105–256.75 (NMS). Source: Nexqual, July 25, 2026 at 04:20 UTC.
Key Statistics (as of July 25, 2026 at 04:20 UTC)
| Price | USD 253.87 |
|---|---|
| Change | ▼ 0.39% (down) |
| Previous Close | USD 254.87 |
| Open | USD 255.83 |
| Day Range | USD 250.3 – 256.75 |
| 52-Week Range | USD 105 – 256.75 |
| Volume | 538,229 shares |
| Market Cap | $15.95B |
| Exchange | NMS |
Technical Analysis (JAZZ)
Nexqual's technical model rates JAZZ "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 04:20 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.23 (neutral) |
| vs SMA50 | Above (USD 237.06) |
| MACD | 5.2 (positive) |
Analyst Ratings (JAZZ)
Wall Street analysts rate JAZZ "Buy" based on 20 analysts, with a mean price target of USD 266.9 (range USD 196–307), per Nexqual as of July 25, 2026 at 04:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 266.9 |
| High Target | USD 307 |
| Low Target | USD 196 |
| Buy / Hold / Sell | 18 / 1 / 1 |
Earnings (JAZZ)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 6.18 |
| Revenue Estimate | $1.11B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 6.34 vs est 4.66 ▲ beat |
| 2025-12-31 | USD 6.64 vs est 6.51 ▲ beat |
| 2025-09-30 | USD 8.13 vs est 5.85 ▲ beat |
| 2025-06-30 | USD -8.25 vs est -6.25 ▼ miss |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financials & Fundamentals (JAZZ)
| Total Revenue | $4.44B |
|---|---|
| Revenue Growth (YoY) | +19.10% |
| Gross Margin | +91.50% |
| Operating Margin | +23.51% |
| Profit Margin | +0.66% |
| ROE | +0.68% |
| Debt / Equity | 119.52 |
| Current Ratio | 2.04 |
| Total Cash | $2.87B |
| Total Debt | $5.42B |
| Free Cash Flow | $1.34B |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Financial Health Score (JAZZ)
Nexqual rates Jazz Pharmaceuticals Plc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 04:20 UTC.
| Growth | Mixed — Revenue +4.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 92%, operating 24% |
| Balance Sheet | Mixed — $2.87B cash vs $5.42B debt |
| Cash Flow | Strong — FCF $1.34B, 31% margin |
| Efficiency | Weak — ROE 1%, ROA 6.9% |
Ownership (JAZZ)
| Insider Ownership | +3.08% |
|---|---|
| Institutional Ownership | +107.98% |
| Shares Outstanding | 62.82M |
| Float | 60.80M |
| Short % of Float | +5.74% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
Leadership (JAZZ)
Jazz Pharmaceuticals Plc is led by Renee D. Gala (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 04:20 UTC.
| President, CEO & Director | Renee D. Gala (age 53) |
|---|---|
| Co-Founder & Chairman | Bruce C. Cozadd (age 61) |
| Executive VP & CFO | Philip L. Johnson (age 61) |
| Senior Vice President of Sleep & CNS Medicine | Jed Black |
Major Backers & Investors (JAZZ)
Notable institutional backers of Jazz Pharmaceuticals Plc include Capital Group, LSV Asset Management, FMR, LLC, according to Nexqual as of July 25, 2026 at 04:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 4.26% |
| LSV Asset Management | 3.8% |
| FMR, LLC | 3.62% |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 3.34% |
| Franklin Resources, Inc. | 3.12% |
| EcoR1 Capital, LLC | 2.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.53% |
| BlackRock | 12.18% |
| State Street | 3.78% |
| Dimensional Fund Advisors | 3.02% |
Source: Nexqual, July 25, 2026 at 04:20 UTC.
From Jazz Pharmaceuticals Plc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Non-oxybate products intended for the treatment of EDS or cataplexy in narcolepsy or IH (Xywav is the first and only FDA-approved therapy to treat IH), including new market entrants, even if not directly competitive with Xywav or Xyrem, could have the effect of changing treatment regimens and payor or formulary coverage of Xywav or Xyrem in favor of other products, and indirectly materially and adversely affect sales of Xywav and Xyrem.
- We developed Rylaze to address the needs of patients and health care providers for an innovative, high-quality erwinia asparaginase with reliable supply.
- Their expertise, resilience, and commitment to patients enable us to advance our strategy with focus and confidence.
- Through direct input from employees, external insights and best practices, we developed our flexible working model; expanding the power of intentional collaboration and our ability to more effectively manage our global and highly distributed team workforce.
Partnerships
- In October 2020, we entered into an amendment to the license agreement with PharmaMar to expand our exclusive license to include rights to develop and commercialize Zepzelca in Canada.
- Under these amendments, we continue to have the right to a meaningful royalty from Hikma on net sales of the Hikma AG product throughout the extended Hikma AG period, which royalty rate was fixed through the end of 2025 and then subject to specified reductions as set forth in our agreement with Hikma.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | USD 59.33 | ▲ 1.59% |
| UTHR | United Therapeutics Corporation | USD 528.47 | ▲ 0.27% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| INCY | Incyte Corporation | USD 117.67 | ▲ 1.62% |
| NBIX | Neurocrine Biosciences, Inc. | USD 175.77 | ▲ 1.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:20 UTC. This page is informational and not investment advice.